Clinical trial
An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd)…
NCT00497770 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00497770 |
|---|---|
| Title | An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed |
| Official title | Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line With Pemetrexed - An Observational Study |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Lung Neoplasms |
| Intervention type | Drug |
| Interventions | Pemetrexed |
| Enrollment | 434 |
| Start date | Feb 1, 2007 |
| Primary completion | Mar 1, 2011 |
| Completion | Mar 1, 2011 |
| First posted | Jul 9, 2007 |
| Last update posted | May 2, 2012 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: